High-Intensity Ultrasound to Shrink the Septum in Hypertrophic Cardiomyopathy
Official title: High-Intensity Ultrasound Ablation for Septal Reduction Therapy of Hypertrophic Cardiomyopathy
Funded at University of Washington · NIH-11307669 · Data updated 2026-11-12
A new, less invasive ultrasound-based treatment is being developed to reduce the thickened heart septum in people with obstructive hypertrophic cardiomyopathy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | September 9, 2023 |
| Project end | February 28, 2027 |
| Funding year | 2026 |
| Award (this year) | $618,982 |
| NIH project number | 5R01HL160712-05 |
| Project ID | NIH-11307669 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adults with obstructive hypertrophic cardiomyopathy who have LVOTO and are considered candidates for septal reduction but are at risk from current surgical or alcohol-based methods.
✕Less likely to help
Patients with non-obstructive HCM or those whose anatomy or health status makes catheter-based HIU unsuitable may not benefit.
What this research studies
This project aims to refine a catheter-based high-intensity ultrasound therapy that targets the thickened heart septum to relieve obstruction in hypertrophic cardiomyopathy. Researchers will optimize how deep and large the lesions are, improve catheter tracking, and verify noninvasive monitoring of the treatment. The study builds on promising animal data and is preparing for early human testing with a focus on safety and effectiveness. The work could lead to a simpler, safer option compared with current septal reduction methods.
Why it matters
Potential benefit: If successful, this approach could reduce symptoms and improve safety for people with obstructive HCM, potentially lowering the need for more invasive procedures.
How similar studies have gone: Preliminary large-animal data suggest that HIU can safely reduce septal tissue with favorable targeting of the mid-myocardium.
Where this research is happening
-
University of Washington
Seattle, United States Active
Researchers
- Principal investigator: Nazer, Babak — University of Washington
- Study coordinator: Nazer, Babak
Related research
Other NIH-funded projects on the same topics.
-
Using ultrasound to treat obstructive hypertrophic cardiomyopathy
This study is testing a new, less invasive treatment for people with obstructive hypertrophic cardiomyopathy (oHCM) that uses ultrasound to help reduce heart muscle blockage, making it a safer option than traditional surgery.
-
Using high-intensity ultrasound to treat heart obstruction in hypertrophic cardiomyopathy
This study is testing a new, less invasive ultrasound treatment for people with obstructive hypertrophic cardiomyopathy (HCM) to help reduce heart muscle thickness and improve heart function.
-
Using ultrasound to treat obstructive hypertrophic cardiomyopathy
This study is testing a new, less invasive ultrasound treatment for people with obstructive hypertrophic cardiomyopathy (oHCM) to help reduce heart blockage safely, especially for those who can't have traditional surgery.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.